Biotech’s comeback looks built to last
The Wall Street Journal - 13-Oct-2025Easing regulations and new drug approvals fuel optimism for a sustained biotech rally
Join the club for FREE to access the whole archive and other member benefits.
Columnist for The Wall Street Journal
David Wainer is a Brazilian-American columnist based in New York who writes for the “Heard on the Street” section of The Wall Street Journal, with a primary focus on the business of healthcare, biotech and pharmaceuticals. He holds a bachelor’s degree in finance and brings together financial market insight and health-industry analysis, regularly exploring topics such as insurance trends, drug-maker strategies and longevity science.
Visit website: https://www.wsj.com/news/author/david-wainer
See alsoDetails last updated 05-Nov-2025
Easing regulations and new drug approvals fuel optimism for a sustained biotech rally
Easing regulations and new drug approvals fuel optimism for a sustained biotech rally